Compare GSK plc (GSK) vs Innovative Industrial Properties Inc (IIPR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Innovative Industrial Properties Inc — how do they compare? GSK plc trades at $52.77 (market cap $101.34B), while Innovative Industrial Properties Inc trades at $65.27 (market cap $1.84B). The key difference: GSK plc is far larger — about 55.1× Innovative Industrial Properties Inc's market cap, and Innovative Industrial Properties Inc pays the higher dividend (11.95%). Which is the better fit depends on your goals.
| GSK | IIPR | |
|---|---|---|
Market Cap | $101.34B | $1.84B |
Sector | Health | Real Estate |
52-Week High | $61.18 | $64.44 |
52-Week Low | $36.20 | $44.58 |
Enterprise Value | $121.95B | $2.23B |
Dividend Yield | 3.49% | 11.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.
The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.
Innovative Industrial Properties (IIPR) trades at $63.83, showing modest daily gains. The technical outlook is bullish based on moving averages, with key support at $61-63 and resistance at $64-66. Fundamentally, the REIT maintains strong gross margins above 88% and a reasonable P/E of 16.22, though revenue declined to $266M in 2025. Recent news highlights successful debt management, including repaying $282M in senior notes and issuing new exchangeable notes, alongside a declared $1.90 quarterly dividend.
Outlook: IIPR presents a high-yield opportunity with a 13% dividend yield, supported by a strengthened balance sheet and potential tailwinds from cannabis rescheduling. Risks include tenant credit quality in the cannabis sector, revenue pressure, and negative cash flow trends. Analyst consensus leans cautious with 36% buy ratings versus 55% hold, suggesting a wait-and-see approach despite the attractive yield.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Innovative Industrial Properties Inc
Innovative Industrial Properties Inc is a real estate investment trust engaged in the acquisition, ownership, and management of specialized industrial properties leased to state-licensed operators for their regulated medical-use cannabis facilities. It conducts its business through a traditional umbrella partnership real estate investment trust, or UPREIT structure, in which properties are owned by Operating Partnership, directly or through subsidiaries. Its property portfolio is spread across the United States.
Read more on IIPR →
